Henry Schein, Inc
) declared that it has completed its 60% equity investment in
BioHorizons, Inc. HSIC first announced its decision to invest in
BioHorizons, on Nov 26, 2013.
BioHorizon is a U.S.-based manufacturer of advanced dental
implant technology and tissue regeneration products that are sold
globally. Henry Schein expects the acquisition to be dilutive to
its earnings per share by 3-5 cents in 2014 and 3-4 cents in
Recent investments made by Henry Schein reveal the company's
strategic intentions to tap lucrative opportunities in the dental
implant market in regions like Europe and the United States. The
company seeks to expand its footprint in the dental implant
market that is expected to rise to $1.5 billion in 2016 from $1.0
billion in 2012, taking into consideration U.S. and Canada alone.
Alongside increased consumer awareness, and high success rates in
implant procedures have helped accelerate growth in this market.
Moreover, the new era of digitization has enhanced patient
comfort, thus improving the overall dental experience for
Recently, HSIC also forged an agreement to acquire 100% ownership
of five businesses operating in three European countries from
Arseus NV. Henry Schein is optimistic about such strategic
investments that should help it garner a prominent position in
the growing dental specialty market. HSIC also has investments in
CAMLOG Biotechnologies AG, a leading manufacturer of dental
implants in Europe.
Moreover, the investment in BioHorizons provides Henry Schein the
chance to strengthen its portfolio in the biologics market, a
critical adjunct to the implant market.
Currently, Henry Schein carries a Zacks Rank #3 (Hold). Investors
interested in the medical dental supplies industry can look at
better-ranked stocks like
Align Technology Inc.
Cardinal Health, Inc
), each carrying a Zacks Rank #1 (Strong Buy) and
) carrying a Zacks Rank #2 (Buy).
ALIGN TECH INC (ALGN): Free Stock Analysis
CARDINAL HEALTH (CAH): Free Stock Analysis
HENRY SCHEIN IN (HSIC): Free Stock Analysis
MCKESSON CORP (MCK): Free Stock Analysis
To read this article on Zacks.com click here.